Ipca Laboratories has announced that its Board of Directors will convene on May 29, 2026. The primary agenda includes the approval of the standalone and consolidated audited financial results for the fourth quarter (Jan-Mar 2026) and the full financial year 2025-26. Additionally, the Board will deliberate on recommending a dividend for the 2025-26 fiscal year to shareholders.
Upcoming Board Meeting Details
Ipca Laboratories is set to hold a crucial Board of Directors meeting on Friday, May 29, 2026. This meeting will focus on the company’s financial performance, specifically reviewing the audited financial results for the fourth quarter and the entire financial year 2025-26, which concluded on March 31, 2026.
Dividend Consideration
In addition to reviewing financial statements, the Board will discuss the potential declaration of a dividend for the financial year 2025-26. Any recommendations made during this meeting regarding payouts will be subject to subsequent disclosures.
Trading Window Restrictions
The company has reminded stakeholders that the trading window for securities remains closed. This restricted period began on April 1, 2026, and will continue until 48 hours after the company’s financial results for the quarter and year ended March 31, 2026, are officially made public, which is slated to conclude on May 31, 2026.
Source: BSE
